Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder

Vidal, Liat; Kneer, W.; Baturone, Manuel Ollero; Sigmund, Ralf

doi:10.1007/pl00022376

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also questioned the rationale for continuous (as opposed to on-request) NSAID treatment in patients with ankylosing spondylitis. [44] The efficacy of meloxicam in reducing acute periarticular shoulder pain was assessed in a multinational, double-blind study by Vidal et al [45] In this 2-week trial, the primary efficacy endpoint of which was patient-assessed pain reduction after 7 days of therapy, 599 patients with soft-tissue rheumatism of the shoulder were randomised to oral treatment with meloxicam 7.5 or 15 mg/day or piroxicam 20 mg/day. The treatments demonstrated similar efficacy in relieving pain at day 7.…”

Section: Other Musculoskeletal Disordersmentioning

confidence: 99%

“…Furthermore, fewer patients in the meloxicam groups discontinued the study due to adverse events. [45] Acute low back pain, usually resulting from unusual movements or strains in the lumbar spinal column, is an extremely painful condition that requires rapid analgesia. Meloxicam 15 mg/day and piroxicam 20 mg/day provided fast pain relief, with a median time to onset of analgesia of 40-45 minutes, in a multicentre, randomised, open study that was conducted in 160 patients with acute low back pain.…”

Section: Unauthorizedmentioning

confidence: 99%

“…Mean scores for pain at rest, on movement and on coughing (measured by VAS at 2, 4, 8, 12 and 24 hours after surgery) were all significantly reduced (by 46, 29 and 23%, respectively) in meloxicam-treated patients compared with placebo, although no significant differences were noted in PCA morphine consumption. [45]…”

Section: Postoperative Painmentioning

confidence: 99%

“…Mean change from baseline in visual analogue scale (VAS) scores for pain on movement in patients with acute extra-articular rheumatism of the shoulder treated with meloxicam 7.5 or 15 mg/day or piroxicam 20 mg/day. * indicates p < 0.05 versus piroxicam [45].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug

Tacca¹,

Colucci²,

Fornai³

et al. 2002

Clinical Drug Investigation

View full text Add to dashboard Cite

Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity. In vitro studies with human tissues have confirmed the high affinity of meloxicam for COX-2, whereas COX-1 was inhibited only at the highest concentrations (ratio of 50% inhibitory concentration for COX-2 : COX-1 = 0.09 in whole blood assays).Meloxicam has a bioavailability of 89% after oral administration, is strongly bound to plasma proteins, and its half-life is 20-24 hours. It readily penetrates into synovial fluid, reaching 45-57% of plasma concentrations. Meloxicam pharmacokinetics are not significantly altered in elderly patients or in those with mild renal/hepatic impairment.The efficacy and tolerability of meloxicam in the treatment of pain and inflammation associated with rheumatic and musculoskeletal disorders has been evaluated in numerous studies comparing meloxicam 7.5-15 mg/day (up to 22.5 mg/day in ankylosing spondylitis), administered for 2 weeks to 12 months, with placebo or other nonsteroidal anti-inflammatory drugs (NSAIDs). Overall, the efficacy of meloxicam was significantly superior to that of placebo and similar to that of other NSAIDs, whereas the incidence of adverse events (especially gastrointestinal) was lower than with other NSAIDs. Intramuscular meloxicam provided faster pain relief than the oral drug in patients with rheumatoid arthritis. Meloxicam also appears to be effective in the prevention of postoperative pain, as shown in patients undergoing abdominal hysterectomy or inguinal hernia repair. Meloxicam may also have a cardioprotective role: in patients with acute coronary syndrome without ST-segment elevation, a lower incidence of cardiovascular events was observed in those who received meloxicam plus aspirin and heparin versus aspirin and heparin alone, both during coronary care stay and at 90-day follow-up.Meloxicam has demonstrated a favourable tolerability profile in large-scale comparative trials, where its gastrointestinal tolerability was superior to that of nonselective NSAIDs. In particular, meloxicam 7.5 mg/day was associated with a lower incidence of gastrointestinal adverse events compared with diclofenac (13% vs 19%; p < 0.001) or piroxicam (10.3% vs 15.4%; p < 0.001). This was confirmed by a prescription-event monitoring study that found a relatively low

show abstract

Section: Other Musculoskeletal Disordersmentioning

confidence: 99%

Section: Unauthorizedmentioning

confidence: 99%

Section: Postoperative Painmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations